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Abstract: The prevalence of cardiovascular diseases (CVD) is rising and is the prime 
cause of death in all developed countries. Bioactive compounds (BAC) can have a role in 
CVD prevention and treatment. The aim of this work was to examine the scientific evidence 
supporting phenolic BAC efficacy in CVD prevention and treatment by a systematic 
review. Databases utilized were Medline, LILACS and EMBASE, and all randomized 
controlled trials (RCTs) with prospective, parallel or crossover designs in humans in which 
the effects of BAC were compared with that of placebo/control were included. Vascular 
homeostasis, blood pressure, endothelial function, oxidative stress and inflammatory 
biomarkers were considered as primary outcomes. Cohort, ecological or case-control studies 
were not included. We selected 72 articles and verified their quality based on the Scottish 
Intercollegiate Guidelines Network, establishing diverse quality levels of scientific 
evidence according to two features: the design and bias risk of a study. Moreover, a grade 
of recommendation was included, depending on evidence strength of antecedents. 
Evidence shows that certain polyphenols, such as flavonols can be helpful in decreasing 
CVD risk factors. However, further rigorous evidence is necessary to support the BAC 
effect on CVD prevention and treatment. 









The prevalence of cardiovascular disease (CVD) is rising and is the prime cause of death in all 
developed countries [1], and one of the most important health issues in developing countries [2]. While 
some risk factors cannot be changed, such as family history, ethnicity and age, detection and control of 
modifiable factors such as, blood pressure (BP), high cholesterol, obesity, type 2 diabetes (T2D) or 
unhealthy diets can help to prevent intermediate risk CVD processes like inflammation or oxidative 
stress. Thus, primary prevention of CVD by identifying and treating at-risk individuals remains a 
major public-health priority. A healthy life style is the main pre-emptive approach [3,4]. 
Dietary habits are quite different around world; nevertheless, certain consumption patterns are 
common worldwide, inclusion of fruits and vegetables or products like cocoa, coffee or condiments is 
a merging point. Bioactive compounds (BAC) are “extra nutritional” constituents that are present in 
small quantities in plant products and lipid rich foods [5]. The growing body of scientific evidence 
indicates that certain BAC play a beneficial role in CVD prevention [6–11]. BAC oral supplements 
along with a usual diet can increase the intake of ingredients reputed to have clinical benefits. These 
supplements are, usually, an addition to the healthy diet, and not as a conventional food or the sole 
item of a meal [12]. 
Putative beneficial biological effects such as antilipidemic, antihypertensive, anti-glycaemic, 
antithrombotic and anti-atherogenic effects are attributed to BAC. In the present study, the main goal 
was to examine the scientific evidence of BAC in the prevention and treatment of CVD by a 
systematic review of randomized clinical trials (RCTs). The BAC considered in this review were all 
those related to the phenolic compounds.  
Phenolic compounds such as stilbenes like the resveratrol (3,5,4′-trihydroxystilbene) can be found 
principally in the skin of grapes and are produced in other plants, such as peanuts [6]. Red wine is a 
rich source of resveratrol and is thought to confer the cardio protective effects associated with 
moderate consumption of wine [13]. Within the catechols family, curcuminoids are multifunctional 
natural compounds found in native Indonesian plants, with promising cardio protective and  
anti-inflammatory properties and mainly present in the dried rhizomes of Curcuma longa L. 
(commonly known as turmeric) [14]. 
In relation to polyphenols, there are six basic subclasses of flavonoids: flavones, anthocyanins, 
flavanones, flavonols, isoflavones, and the flavanols, including the flavanol oligomers, the 
proanthocyanidins that are further subdivided into 16 species including the procyanidins, oligomers of 
the flavan-3-ols catechin and epicatechin, and the prodelphinidins, oligomers of the gallocatechins [15]. 
In this review, we utilized equations to divide the results according to the most relevant classes. 
Specifically, we examined the effects of BAC on BP, lipid profile [triacylglycerol (TAG), cholesterol, 
high and low density lipoproteins(HDL and LDL)], carbohydrate (CHO) metabolism (glucose, insulin, 
and insulin resistance (IR)), oxidative stress, inflammation and endothelial function (EF). Furthermore, 
we gave a recommendation for consumption based on the evidence grade according to Scottish 
Intercollegiate Guidelines Network (SIGN) [16]. 
  




We developed a literature search in Medline by PubMed (U.S. National Library of Medicine and the 
NIH), and in LILACS and EMBASE, including publications in English, Spanish and Portuguese until 
December 2014. Studies eligible for this review included: randomized controlled trials (RCTs) in 
healthy and unhealthy adults, with prospective, parallel or crossover designs, with full text, and whose 
primary outcomes were vascular homeostasis, BP, oxidative stress and/or inflammatory biomarkers; 
we excluded those studies with cohort, ecological or case-control design, those which analysed a drug, 
or when BAC were combined with other compounds. However, there was no restriction on publication 
type or sample size. 
2.1. Search Equation 
Due to the diversity of the chemical structures of phenol compounds (Figure 1), the type of BAC can 
present different effects in CVD; consequently, we evaluated the more relevant groups. We included 
different keywords in the search equation of bioactive compounds, including: Phenols (stilbenes, 
catechols, flavonoids, anthocyanins, flavanones, isoflavones, polyphenols, phenolic acids, gallic acid 
and hydroquinones). We combined the MeSH term “cardiovascular diseases” with each bioactive 
compound as MeSH Major Topic, together with NOT “review” (Publication Type) in PubMed. 
However, equations in the Spanish language were used when the search was carried out in LILACS 
i.e., (tw:(polifenoles)) AND (tw:(enfermedad cardiovascular)) AND NOT (tw:(revisión)). When 
consulting the database EMBASE, the equations were elaborated as “catechols”/mj AND 
“cardiovascular diseases”/mj “NOT review”. Articles published before 1990 were discarded because 
they did not comply the inclusion criteria stablished. 
 
Figure 1. Chemical diversity polyphenols. Simple phenols are represented by (a) catechols 
and (b) stilbenes, and polyphenols in (c) anthocyanins, (d) flavonols, (e) flavanols and  
(f) isoflavones. 
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After the review process by proofreading staff, we included four additional articles. Three of them 
were not located by our search criteria; the other appeared in our initial search, but its main outcome in 
relation to exercise did not comply with the requirement for inclusion in the review. Nevertheless, after 
a second approach by the proofreading staff, we also decided to include it (see footnotes in the  
Tables 1–3). 
2.2. Selection and Evaluation 
First, both titles and abstracts were identified independently by two reviewers, for exclusion of those 
articles that did not fit with the language, date, subject matter, design and outcomes established. Then, 
full-text publications were classified by pathologies according to outcomes analysed in each study. 
Moreover, RCTs were finally selected if they obtained a score between 3 and 5 according to the 
Jadadscale [17]. This method attempts to reduce bias for RCTs, ensuring a certain quality in the evidence; it 
took into account if they were randomized, blinded and provided detailed information about patients. 
Furthermore, we verified the quality of selected articles by the Scottish Intercollegiate Guidelines 
Network (SIGN) [16]. Diverse quality levels of scientific evidence are established according to two 
features: the design and bias risk of a study. The levels are from 1++, when the information is 
considered as high quality, to 4 when the information is considered as very low quality. Signs are used 
to reporting with reference to compliance degree of key criteria associated with potential bias (1++, 1+, 
1-, 2++, 2+, 2-, 3, and 4). Additionally, we included a grade of recommendation, based on the evidence 
strength of the antecedents, whose levels are A, B, C, D, with “A” being highly recommended and “D” 
not recommended. These grades of recommendation by SIGN guidelines are equivalent to those 
designated by the Food and Agriculture Organization of the United Nations/World Health Organization 
(FAO/WHO), as evidence criteria: convincing, probable, possible and insufficient [18]. 
3. Results and Discussion 
In total, 831 RCT’s were found using the equations proposed in the different databases (EMBASE, 
LILACS and PubMed). We excluded 717 due to obvious irrelevance, leaving 114 papers in full to read 
(Figure 2). After papers were read and evaluated using the Jadad scale, 76 articles were selected for the 
final review, and are included in Tables 1–3. 




Figure 2. Review Flow Diagram. 
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Table 1. RCTs of phenolic compounds (catechols, stilbenes and beer/wine) in CVD risk. 





(n) Population Intervention Outcomes Significant Results 
Phenols 
(Stilbenes) 
Wong et al. 
(2011) [19] 
5 2B, X (1 h) 
(19) Overweight/obese + 
↑ BP men or  
post-menopausal women 
30 mg, 90 mg, 270 mg  
RSV vs. PCB  
EF 




Wong et al. 
(2013) [20] * 
5 2B, X (1 h) (28) obese subjects  
Acute intervention: 75 mg/ 
trans-resveratrol (Resvida) vs.  
PCB after chronic intervention 
FMD ↑ FMD 
Phenols 
(Stilbenes) 
Wong et al. 
(2013) [20] * 
5 
2B, X  
(6 weeks) 
(28) obese subjects  
75 mg/day trans-resveratrol  
(Resvida) vs. PCB 
BP, AR, BMI, FMD ↑ FMD 
Phenols 
(Stilbenes) 
Bo et al.  
(2013) [21] 
5 
2B, X (60 
days(wash-
out 30 days)) 
(50) Healthy smokers 500 mg RSV/d vs. PCB 
BP, Anthropometry,  
lipids profile, CHO  
metabolism, TAS, hsCRP,  
↓ hsCRP, TAG, ↑ TAS 
Phenols 
(Stilbenes) 
Militaru et al. 
(2013) [22]  
3 
2B, Ctrl, PA 
(60 days) 
(166) BMI  
24–27 kg/m2,  
stable angina pectoris 
20 mg/day RSV, 20 mg/day  
RSV + 112 mg/day CF,  
112 mg/day CF 
Lipids profile, hsCRP, left 
ventricular function markers 
↓ TC, TAG greater in  
RSV, hsCRP greater  
in CF, NT-proBNP  




et al. (2013) 
[23]  
4 
3B, PCB  
(1 year) 
(75) Stable  
CAD patients 
350 mg/day GE, 350 mg/day  
GE-RES vs. PCB (6 months); 
double dose next 6 months 
PBMCs, inflammatory and 
fibrinolytic biomarkers 
↑ adiponectin, ↓ PAI-1, 
significantly activated or 
inhibited 6 key 
inflammation-related 





et al. (2012) 
[24]  
4 
3B, PCB  
(6 months) 
(75) Primary prevention 
of CVD 
350 mg/day GE, 350 mg/day  
GE-RES vs. PCB 
Lipids profile, oxidized LDL 
↓ LDLc, ApoB, LDLox  
and LDLox/ApoB ratio, ↑ 
nonHDLc/ApoB ratio in  
GE-RES 
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Table 1. Cont. 
















(35) T2D, HT with CAD 
350 mg/day GE, 350 mg/day  
GE-RES vs. PCB (6 months); 
double dose next 6 months 
PBMCs, inflammatory, 
fibrinolytic biomarkers 
↓ CCL3, IL-1β, TNF-α 
expression, ↑ 
transcriptional  
repressor LRRFIP-1 in 




et al. (2012) 
[26] 
4 
3B, PCB  
(1 year) 
(75) Primary prevention 
of CVD 
350 mg/day GE, 350 mg/day  
GE-RES vs. PCB (6 months); 
double dose next 6 months 
Inflammatory and 
fibrinolytic biomarkers 
↓ CRP, TNF-α, PAI-1, 
IL-6/IL-10 ratio, sICAM 




Alwi et al. 
(2008) [27]  
4 
2B, PCB  
(2 months) 
(75) ACS patients 
45 mg/day, 90 mg/day or  
180 mg/day curcumin vs. PCB 




et al. (2014) 
[28] 
5 
2B, PCB  
(6 months) 
(240) T2D patients 750 mg/day curcumin vs. PCB  
BP, anthropometry, lipids 
profile, adiponectin, leptin, 
CHO metabolism, PWV, 
uric acid 
↓ PWV, HOMA, TAG, 
uric acid, abdominal 









X (4 weeks) 
(61) HT subjects 
280 mg/day red wine polyphenols  
or 560 mg/day red wine  
polyphenols vs. PCB 
BP No significant effect 
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Table 1. Cont. 





(n) Population Intervention Outcomes Significant Results 
Polyphenols 
(Wine/beer) 
Chiva-Blanch et al. 
(2014) [30]  
4 
2B, PCB, X 
(4 weeks) 
(36) High risk of  
CVD males 
Beer (30 g alcohol/day), the 
equivalent amount of polyphenols 
in the form of non-alcoholic beer, 
or gin (30 g alcohol/day) 
Circulating endothelial 
progenitor cells and  
EPC-mobilizing factors 
Beer and non-alcoholic 
beer interventions,  
↑-circulating EPC. No 
significant differences 




Chiva-Blanch et al. 
(2012) [31]  
3 X (4 weeks) 
(67) High risk of  
CVD males 
Red wine (30 g alcohol/day), the 
equivalent amount of dealcoholized 
red wine, or gin (30 g alcohol/day) 
BP and plasma nitric oxide 
Dealcoholized red wine ↓ 
DBP and SBP 
Polyphenols 
(Wine/beer) 
Chiva-Blanch et al. 
(2012) [32]  
3 X (4 weeks) 
(67) High risk of  
CVD males 
Red wine (30 g alcohol/day), the 
equivalent amount of dealcoholized 
red wine, or gin (30 g alcohol/day) 
Inflammatory biomarkers 




compounds of Red wine ↓ 
serum concentrations of 
ICAM-1, E-selectin, and 
IL-6 
2B, double-blinded, 3B, triple-blinded, ACS, acute coronary syndrome; Apo, apolipoprotein; BMI, body mass index; BP, blood pressure; CAD, chronic artery disease; 
CHO, carbohydrate; CCL-3, chemokine (C–C motif) ligand 3 CRP, C-reactive protein; hsCRP, high sensitivity c-reactive protein; Ctrl, control, CVD, cardiovascular 
disease; EF, endothelial function; EPC, endothelial progenitor cells; FMD, flow mediated dilation; GE, grape extract; GE-RES, grape extract containing RSV (8mg); 
HDLc, high-density lipoprotein cholesterol; HOMA, homeostasis model assessment; HT, hypertension; sICAM, soluble intercellular adhesion molecule; IL, interleukin; 
LDLc, low-density lipoprotein cholesterol; LDLox, oxidized LDL; LRRFIP-1, leucine rich repeat (in FLII) interacting protein 1; NT-proBNP, N-terminal prohormone of 
brain natriuretic peptide; PAI-1, plasminogen activator inhibitor-1; PCB, placebo, PBMCs, peripheral blood mononuclear cells; PWV, pulse wave velocity; RSV, 
resveratrol;  TAG, triacylglycerols; TC, total cholesterol; TNF-α,tumour necrosis factor alpha; T2D, type 2 diabetes; X, crossover design. * Included after proofreading. 
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2B, PCB,  
X (14 days) 
(30) Healthy 
females 
330 mL/day beverages (PCB, 
juice or smoothie with 8.9, 983.7 
and 840.9 mg/L ACN, 
respectively) 
Inflammatory and  
oxidative stress biomarkers 
↑ SOD and CAT after ACN. 




Curtis et al. 
(2009) [34] 
5 





500 mg/day ACN vs. PCB  
BP, CHO metabolism, 
lipids profile, inflammatory 
biomarkers,  
platelet reactivity 




et al. (2013) 
[35]  
5 
2B, PCB,  




640 mg/day ACN vs. PCB 
Lipids profile, CHO 
metabolism, inflammatory 
and oxidative stress 
biomarkers 
↑ HDLc and glucose after 
anthocyanin versus PCB 
treatment. No effects were 
observed on inflammation 
or oxidative stress in vivo, 




et al. (2011) 
[36]  
4 
Open-label, (2 and 
4 hour acute study) 
(15) CAD 
subjects 
835 mg total polyphenols,  
94 mg anthocyanins vs. PCB 




et al. (2011) 
[36] 
4 
X, 2B, PCB (4 




835 mg total polyphenols,  
94 mg anthocyanins vs. PCB 
Vascular function 
↓ Carotid femoral  
pulse wave activity 
Flavonoids 
(Catechins) 
Miyazaki et al. 
(2013) [37] 
4 




630.9 mg/day Green  
Tea Catechins vs. Ctrl 
CVD risk markers No significant effect 
Flavonoids 
(Catechins) 
de Maat et al. 
(2000) [38]  
3 




Black tea (3 g/day), green tea  
(3 g/day), green tea polyphenol 





between the levels of the 
antioxidant β-carotene and 
the inflammation markers 
IL6 and fibrinogen 
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Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Catechins) 
Widmer et al. 
(2013) [39] 
3 2B, Ctrl (4 months) 
(52) Early 
atherosclerosis 
30 mL/day simple Olive Oil vs.  
30 mL/day of  
EGCG-supplemented Olive Oil 
EF, inflammation and 
oxidative stress 
Only significant when 
merging data of both groups 
the EF was improved. 
Flavonoids 
(Catechins) 
Nagao et al. 
(2007) [40]  
4 2B, PA (12 weeks) 
(240) Visceral 
fat-type obesity 
Green tea containing 583 mg/day 
catechins (catechin group) vs.  
96 mg/day catechins (Ctrl group)  
Anthropometric 
measurements, body fat 
composition and CVD risk 
↓ body weight, BMI, body 
fat ratio, body fat mass, 
waist circumference, hip 
circumference, visceral fat 
area, and subcutaneous fat 
area, SBP, LDLc 
Flavonoids 
(Flavanols) 
Farouque et al. 
(2006) [41]  
5 2B, PCB (6 weeks) 
(40) Healthy 
males 
Flavanol-rich chocolate bar and 
cocoa beverage (total flavanols, 
444 mg/day) vs. matching 
isocaloric PCBs (total flavanols, 
19.6 mg/day)  
EF and adhesion molecules No significant effect 
Flavonoids 
(Flavanols) 
Berry et al. 
(2010) [42] * 
4 
2B, X (2 h,  




HF, 701 mg or LF, 22 mg cocoa BP, HR, FMD 
↑ DBP after exercise were 
attenuate by HF, 




Davison et al. 
2008 [43] * 
4 





902 mg cocoa flavanols/day vs.  
36 mg cocoa flavanols/day 
With/without exercise protocol 
BP, HDLc, LDLc, TG, 
HOMA, FMD 
↑ FMD at 6 and 12 weeks 
with HF vs. LF, ↑ DBP, BP 
mean, improvement in 
HOMA (independent  
of exercise) 
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Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Flavanols) 
West et al. 
(2014) [44]  
3 
2B, PCB, X  




37 g/day of dark chocolate and a 
sugar-free cocoa beverage  
(total flavanols = 814 mg/day) vs. 
low-flavonol chocolate and  
cocoa free beverage  
(total flavanols = 3 mg/day) 
EF, BP 
↑ Basal and peak diameter 
of the brachial artery and 
basal blood flow volume. 
Flavonoids 
(Flavanols) 
Faridi et al. 
(2008) [45] 
4 
X, Ctrl, 1B (1 days, 
7 days washout) 
(45) Overweight 
subjects 
Solid dark chocolate bar (821 mg 
flavanols) vs. cocoa-free PCB bar 
(0 mg flavanols) 
EF, BP 
Solid dark chocolate 
improved EF; also ↓ BP 
Flavonoids 
(Flavanols) 
Faridi et al. 
(2008) [45] 
4 
X, Ctrl, 1B (1 days, 
7 days washout) 
(44) Overweight 
subjects 
Sugar-free cocoa (805.2 mg 
flavanols), sugared cocoa  
(805.2 mg flavanols), vs.  
PCB (0 mg flavanols). 
EF, BP 
Liquid cocoa ingestion 
improved EF; sugar-free 
cocoa ↓ BP 
Flavonoids 
(Flavanols) 
Davison et al. 
(2010) [46] 
3 2B, PA (6 weeks) 





33, 372, 712 or 1052 mg/day  
of cocoa flavanols 
24-h BP No significant effect 
Flavonoids 
(Flavanols) 
Grassi et al. 
(2008) [47]  
3 
X, Ctrl, 1B  
(15 days) 
(19) HT with 
Impaired glucose 
tolerance 
Flavonol-rich dark chocolate 
(110.9 mg epicatechin, 36.12 mg 
catechin, 2.5 mg quercetin,  
0.03 mg kaempferol, and 0.2 mg 
isorhamnetin)/d or  
flavonol-free white chocolate 
(0.04 mg/day catechins) 
EF, IR, β-cell function, 
BP, CRP, TC 
↓ IR, BP, TC, LDLc. ↑ 
insulin sensitivity, EF 
  
Nutrients 2015, 7 5188 
 
 






Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Flavanols) 
Flammer et al. 
(2012) [48] 
3 2B, PCB (2 hours) (20) CHF patients 
40 g Flavonol rich chocolate  
(624 mg total flavanols) vs. 28.4 g 
Ctrl chocolate (0 mg flavanols 
EF and platelet function in 
the short term 
Improvement of  
vascular function in  
patients with CHF 
Flavonoids 
(Flavanols) 
Flammer et al. 
(2012) [48] 
3 
2B, PCB  
(2 and 4 weeks) 
(20) CHF patients 
40 g/day Flavonol rich chocolate 
(624 mg total flavanols) vs.  
28.4 g/day Ctrl chocolate  
(0 mg flavanols) 
EF and platelet function in 
long term by FMD 
Improvement of  
vascular function in  
patients with CHF 
Flavonoids 
(Flavanols) 
Heiss et al. 
(2010) [49] 
3 




High-flavanol intervention  
(375 mg/day) and a 
macronutrient- and micronutrient-
matched  
low-flavanol intervention  
(9 mg/day) twice daily 
EF and enhancement and 
function of circulating 
angiogenic cells 
↑ EF, CD34+/KDR+-
Circulating angiogenic  
cells. ↓ SBP 
Flavonoids 
(Flavanols) 
Horn et al. 
(2013) [50]  
3 2B, X (30 days) 
(16) CAD 
patients  
High-flavanol intervention  
(375 mg/day) and a 
macronutrient- and micronutrient-
matched low-flavanol 
intervention (9 mg/day) twice 
daily 
Circulating endothelial 
micro particles, markers of 
endothelial integrity, EF 
↑ Endothelial  
micro-particles and EF. 




Balzer et al. 
(2008) [51]  
5 
2B, PCB,  
three-period X (2 h) 
(10) Diabetic 
subjects 
Single-dose ingestion of cocoa, 
containing increasing 
concentrations of flavanols  
(75, 371, and 963 mg) 
EF 
Single ingestion of  
flavanol-containing cocoa 
was dose-dependently acute 
increases in circulating 
flavanols and EF  
Flavonoids 
(Flavanols) 
Balzer et al. 
(2008) [51] 
5 




963 mg/day Flavanol-rich cocoa  
vs. nutrient-matched Ctrl  
(75 mg/day flavanols) 
EF 
Flavanol-containing cocoa ↑ 
baseline EF 
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Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Flavonols) 
Larson et al. 
(2012) [52]  
3 
2B, PCB, X (1 days, 
7 days washout) 
(5) Healthy males 
1095 mg quercetin aglycone vs. 
PCB 
Angiotensin-converting 
enzyme, endothelin-1, BP 
No significant effect 
Flavonoids 
(Flavonols) 
Conquer et al. 
(1998) [53] 
3 2B (28 days) 
(27) Healthy 
subjects 
4 capsules (1.0 g quercetin/day) 
vs. rice flour PCB 
BP, lipids profile, 
thrombogenic risk factors 
No significant effect 
Flavonoids 
(Flavonols) 
Suomela et al. 
(2006) [54] 
3 
2B, PCB, X  




Oat meal with 78 mg/day flavonol 
aglycones (sea buckthorn) vs. Ctrl  
CVD risk markers No significant effect 
Flavonoids 
(Flavonols) 
Edwards et al. 
(2007) [55] 
3 





730 mg quercetin/day vs. PCB BP, oxidative stress ↓ BP in hypertensive group 
Flavonoids 
(Flavonols) 
Larson et al. 
(2012) [52]  
3 
2B, PCB, X (1 days, 
2 days washout) 
(12) HT  
stage 1 males 
1095 mg quercetin  
aglycone vs. PCB 
Angiotensin-converting 
enzyme, endothelin-1, BP 
↓ BP in Hypertensive men  
8-iso-PGF2α, 8-iso-prostaglandin F2α; 1B, one-blind, 2B, double-blinded; ACN, anthocyanins; Apo, apolipoprotein; BMI, body mass index; BP, blood pressure; CAD, 
chronic artery disease; CAT, catalase; CHF, chronic heart failure; CHO, carbohydrate; CRP, C-reactive protein; hsCRP, high sensitivity c-reactive protein; Ctrl, control, 
CVD, cardiovascular disease; DXA, Dual-energy X-ray absorptiometry; EF, endothelial function; EGCG, epigallocatechin gallate; ESRD, European and North American 
end-stage renal disease; FM, fat mass; FFM, fat-free mass; FMD, flow mediated dilation; HDLc, high-density lipoprotein cholesterol; HOMA, homeostasis model 
assessment; HR, heart rate; HT, hypertension; sICAM, soluble intercellular adhesion molecule; IGF-1, insulin-like growth factor-1; IR, insulin resistance; IL, interleukin; 
LDLc, low-density lipoprotein cholesterol; MDA, malonaldehyde; MPFF, micronized purified flavonoid fraction; MPI, milk protein isolate; NTG, nitro-glycerine-mediated 
dilation; PA, parallel design, PAI-1, plasminogen activator inhibitor-1; PCB, placebo, PBMCs, peripheral blood mononuclear cells; PS, plant sterols; PWV, pulse wave 
velocity; QUICKI, quantitative insulin sensitivity check index; SBP, systolic blood pressure; SOD, superoxide dismutase; TC, total cholesterol; TGF, transforming growth 
factor; T2D, type 2 diabetes; VCAM, soluble vascular cellular adhesion molecule; vWf, von Willebrand factor; X, crossover design. * Included after proofreading. 
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Table 3. RCTs of polyphenols (isoflavones and procyanidins) in CVD risk. 
Group (Class) Author/Date 
Jadad  
Score 
Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Isoflavones) 
McVeigh et al. 
(2006) [56] 
3 
1B, X (57 days,  
4 weeks washout) 
(35) Healthy 
males 
Milk protein isolate (MPI),  
low-isoflavone soy protein  
isolate (low-iso SPI; 1.64 ± 0.19 
mg aglycone isoflavones/day), 
and high-isoflavone SPI  
(high-iso SPI; 61.7 ± 7.4 mg 
aglycone isoflavones/day)  
Lipids profile 
↓ TC/HDLc, LDLc/HDLc, 
and Apo B/Apo A-I with both 




Sanders et al. 
(2002) [57]  
3 




56 vs. 2 mg isoflavones/day 
Lipids profile, fibrinogen,  
and active TGF-β, factor  
VII coagulant and PAI-1 




Thorp et al. 
(2008) [58] * 
5 





24 g SP+70–80 mg  
ISOs (diet S) vs. 12 g SP + 12 g  
dairy protein (DP) + 70–80 mg  
ISOs (diet SD) vs. 24 g DP  
without ISOs (diet D) 
HDLc, LDLc, TC No significant effect 
Flavonoids 
(Isoflavones) 
Atkinson et al. 
(2004) [59]  
5 
2B, PCB  
(12 months) 
(205) Female 
43.5 mg red clover-derived 
isoflavones/day vs. PCB 
Lipids profile, BP,  
fibrinogen and PAI-1 
No significant effect 
Flavonoids 
(Isoflavones) 
Marini et al. 





with low  
bone mass 
54 mg/day genistein aglycone  
vs. PCB 
Lipids profile, CHO  
metabolism, HOMA, fibrinogen, 
osteoprotegerin and homocysteine 
↓ fasting glucose and insulin, 




Hodis et al. 
(2011) [61]  
5 





25 g/day soy protein (91 mg/day 
aglycone isoflavone equivalents) 
vs. PCB 
Atherosclerosis progression No significant effect 
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Table 3. Cont. 
Group (Class) Author/Date 
Jadad  
Score 
Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Isoflavones) 
Atteritano et al. 
(2007) [62] 
5 





54 mg/day genistein vs. PCB 
Lipids profile, CHO metabolism, 
HOMA, fibrinogen, sVCAM-1, 
sICAM-1, 8-iso-PGF2α, and 
osteoprotegerin 
↓ Fasting glucose and insulin 
as well as HOMA, 
fibrinogen, 8-iso-PGF2α, 




Garrido et al. 
(2006) [63]  




100 mg/day isoflavones vs. PCB 
Lipids profile, CHO metabolism 
and platelet thromboxane A2 
receptor density. BP, BMI, 
subcutaneous fat 




Hall et al. 
(2005) [64]  
4 
2B, PCB, X  






(genistein-to-daidzein ratio  
of 2:1; 50 mg/day) vs. PCB 
cereal 





Rios et al. 
(2008) [65]  




40 mg/day isoflavone vs.  
casein PCB 
Lipids profile No significant effect 
Flavonoids 
(Isoflavones) 
Villa et al. 
(2009) [66]  




54 mg/day genistein vs. PCB 
Anthropometric measures, lipid 
profile, CHO metabolism and  
C-peptide evaluation, IR and EF 
HOMA and fasting glucose 
levels significantly improved 
Flavonoids 
(Isoflavones) 
Liu et al. 
(2012) [67]  




15 g/day soy protein and  
100 mg/day isoflavone (Soy 
group), vs. 15 g/day milk protein 
and 100 mg/day isoflavone  
(Iso group) vs. 15 g/day milk 
protein (PCB) 
Lipids profile, inflammatory 
markers and composite 
cardiovascular 
No significant effect 
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Table 3. Cont. 
Group (Class) Author/Date 
Jadad  
Score 
Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Isoflavones) 
Yang et al. 









35 mg/day vs. 70 mg/day soy 
extractª 
Lipids profile 
↓ TC, LDLc in patients  
with TC >200 mg/dL 
Flavonoids 
(Isoflavones) 
Liu et al. 
(2013) [67] 




40 g/day soy flour (whole soy 
group), 40 g/day low-fat milk 
powder + 63 mg/day daidzein 
(daidzein group), vs. 40 g/day low-
fat milk powder (PCB)  
Anthropometric indicators  
and body composition 




Leheudre et al. 
(2008) [69] 




70 mg/day isoflavones vs. PCB 
Body composition (DXA),  
and Lipid profile and CHO 
metabolism 
No significant effect 
Flavonoids 
(Isoflavones) 
Choquette et al. 
(2011) [70]  






PCB or isoflavones (70 mg/day) or 
exercise + PCB or exercise + 
isoflavones (70 mg/day). Exercise 
consisted of three weekly sessions  
of resistance training  
and aerobics 
Body composition, lipids profile, 
CHO metabolism and HOMA. 




Leheudre M  








70 mg/day isoflavonesb (+weight 
loss exercise program from the 6 
months) vs. PCB 
Anthropometry, lipids profile,  
CHO metabolism, CRP 
↓ body weight, BMI, total 
and abdominal FM (kg and 




Hodgson et al. 
(1999) [72] 
3 




55 mg/day isoflavonoid vs. PCB 8-iso-PGF2α No significant effect 
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Table 3. Cont. 
Group (Class) Author/Date 
Jadad  
Score 
Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Isoflavones) 
Sagara et al. 
(2004) [73]  
3 
PCB, 2B, PA  
(5 weeks) 
(61) Men with 
relatively higher BP 
or TC 
Diets containing at least 20 g/day soy 
protein + 80 mg/day isoflavones vs. 
PCB diets 
BP and Lipid profile 
↓ BP, TC and non-HDLc  
and ↑ HDLc. 
Flavonoids 
(Isoflavones) 
Clerici et al. 
(2007) [74] 
4 Ctrl, PA (8 weeks) 
(62) 
Hypercholesterolemia 
80 g serving/d (33 mg/day 
isoflavones + negligible soy protein + 
led to a serum isoflavone 
concentration of 222 +/- 21 nmol/L) 
vs. Ctrl group 
Lipids profile, hsCRP,  
urinary 8-iso-PGF2α,  
and EF 
↓ LDLc, TC 
Flavonoids 
(Isoflavones) 
Meyer et al. 
(2004) [75]  
3 





Soy-based milk (30 g/day soy protein 
+ 80 mg/day isoflavones) + yoghurt 
(treatment) vs. equivalent dairy 
products (Ctrl) 
BP, arterial compliance,  
lipid profile, fatty acids  
No significant effect 
Flavonoids 
(Isoflavones) 
Jenkins et al. 
(2002) [76]  
3 
1B (1 month,  




A low-fat dairy food Ctrl diet, high- 
(50 g soy protein and 73 mg 
isoflavones/day), low- (52 g soy 
protein and 10 mg isoflavones/day) 
isoflavone soy food diets 
BP, lipids profile, oxidized 
LDL, calculated CAD risk 
Soy diets ↓ TC estimated 
CAD risk, TC/HDLc, 
LDLc/HDLc, ApoB/A-I. 
Blood lipid and BP changes, 
the calculated CAD risk ↓ 
with the soy diets 
Flavonoids 
(Isoflavones) 
Blum et al. 
(2003) [77]  
4 
2B, PCB, X  





25 g/day soy protein vs. PCB 
Vascular inflammation  
biomarkers 
No significant effect 
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Table 3. Cont. 
Group (Class) Author/Date 
Jadad  
Score 
Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Isoflavones) 
Teede et al. 
(2006) [78]  




Soy cereal (40 g/day soy protein +  
118 mg/day isoflavones) vs. gluten  
PCB cereal 
BP, arterial function 
↑ 24 hour HR, area under 
curve of 24 h SBP 
Flavonoids 
(Isoflavones) 
Cicero et al. 
(2013) [79]  
4 
Ctrl, 1B prospective 






60 mg/day soy isoflavones + 
500 mg/day berberine vs. PCB (1 
tablet/d) 
BP, HOMA, lipids profile, 
metalloproteinase 
Isoflavones-berberine 
experienced a significant 
improvement in plasma  




Curtis et al. 
(2013) [80] 
5 




women with T2D 
27 g/day flavonoid-enriched 
chocolate (containing 850 mg flavan-
3-ols  
[90 mg epicatechin] + 100 mg 
isoflavones [aglycone equivalents)] /d) 
vs. PCB. 
Intima-media thickness of the 
common carotid artery, pulse 
wave velocity, augmentation 
index, BP, and vascular 
biomarkers 




Curtis et al. 
(2013) [80] 
5 PA, PCB (1 year) 
(93) 
Postmenopausal 
women with T2D 
27 g/day flavonoid-enriched 
chocolate (containing 850 mg flavan-
3-ols  
[90 mg epicatechin] + 100 mg 
isoflavones [aglycone  
equivalents)] /d) vs. PCB. 
 HOMA and QUICKI, lipid 
profile, BP 
Estimated 10-year total 
coronary heart disease risk 
(derived from UK 
Prospective Diabetes Study 
algorithm) was attenuated 
after flavonoid intervention 
Flavonoids 
(Isoflavones) 
Chan et al. 
(2008) [81] 
5 




80 mg/day isoflavone supplement  
vs. PCB 
EF, nitro-glycerine-mediated 
dilatation, BP, HR, CHO 
metabolism, haemoglobin 
A1c, and oxidative  
stress biomarkers 
↓ serum hsCRP and  
improved brachial EF in 
patients with clinically 
manifest atherosclerosis 
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Table 3. Cont. 
Group (Class) Author/Date 
Jadad  
Score 
Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Isoflavones) 
Webb et al. 
(2008) [82]  
4 2B, PA (5 days) 
(71) Subjects with 
CAD 
Isoflavone-intact soy protein  
(75 mg/day of isoflavones) vs.  
isoflavone-free PCB 
Stimulated coronary  
blood flow, Basal and 
stimulated coronary  
artery luminal diameters 
No significant effect 
Flavonoids 
(Isoflavones) 
Fanti et al. 




study (8 weeks) 
(32) ESRD patients 
with systemic 
inflammation 
Nutritional supplements (soy groups) 
containing 26–54 mg isoflavones 
aglycones vs. isoflavone-free  
milk-based supplements (Ctrl group) 
Inflammatory 
biomarkers 
Inverse correlation between 
blood isoflavones levels and 
CRP, positive correlation 
between blood isoflavones 
levels and IGF-1 
Flavonoids 
(Procyanidins) 
Ras et al. 
(2013) [84]  
5 
2B, PCB, PA  
(8 weeks) 
(70) Healthy subjects 
300 mg/day Grape Seed  
Extract vs. PCB 
BP No significant effect 
Flavonoids 
(Procyanidins) 
Yubero et al. 
(2013) [85] 
3 
2B, PCB, X  
(56 days) 
(60) Healthy subjects 
700 mg/day the Grape Extract  
(Eminol®) vs. PCB 
CVD risk and oxidative 
stress markers 




Asher et al. 
(2012) [86]  
5 
2B, PCB,  
four-period X  
(3.5 days, 4 days 
washout) 
(21) Pre-hypertensive 
or mildly hypertensive 
adults 
Hawthorn Extract (1000, 1500,  
and 2500 mg/day) vs. PCB  
EF and nitric oxide 
release 
No significant effect 
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Table 3. Cont. 
Group (Class) Author/Date 
Jadad  
Score 
Design (Follow up) (n) Population Intervention Outcomes Significant Results 
Flavonoids 
(Procyanidins) 
Liu et al. 
(2004) [87] 
3 




100 mg/day Pycnogenol vs. PCB Endothelin 
↓ Calcium antagonist 
nifedipine. ↓ endothelin-1 




Enseleit et al. 
(2012) [88] 
5 
2B, PCB, X  
(8 weeks,  




200 mg/day Pycnogenol vs. PCB 
EF, oxidation and 
inflammatory markers, 
platelet adhesion and 24 h BP 




Mellen et al. 
(2010) [89]  
3 
2B, PCB, X  




1300 mg/day muscadine grape  
seed vs. PCB 
EF, oxidation and 
inflammatory markers, 
antioxidant status 
No significant effect 
Flavonoids 
(Procyanidins) 
Tauchert et al. 
(2002) [90] 
3 





1800 mg/day crataegus extract WS 
1442 or 900 mg/day crataegus extract 
WS 1442 vs. PCB 
Typical heart failure 
symptoms 
Typical heart failure 
symptoms as rated by  
the patients were ↓ to a 
greater extent  
ªSoy extract contains: contains 17.5 mg soy isoflavones consisting of 5.25 mg glycitin, 8.75 mg daidzein, and 3.5 mg genistein; b 44 mg of daidzein, 16 mg of glycitein, 
and 10 mg of genistein; c Soy groups in three formats: Protein powder (54mg isoflavones), Cereal-like product (26mg isoflavones), energy bar (26 mg isoflavones).  
8-iso-PGF2α, 8-iso-prostaglandin F2α; 1B, one-blind, 2B, double-blinded; ACN, anthocyanins; Apo, apolipoprotein; BMI, body mass index; BP, blood pressure; CAD, 
chronic artery disease; CAT, catalase; CHF, chronic heart failure; CHO, carbohydrate; CRP, C-reactive protein; hsCRP, high sensitivity c-reactive protein; Ctrl, control, CVD, 
cardiovascular disease; DXA, Dual-energy X-ray absorptiometry; EF, endothelial function; EGCG, epigallocatechin gallate; ESRD, European and North American end-stage 
renal disease; FM, fat mass; FFM, fat-free mass; HDLc, high-density lipoprotein cholesterol; HOMA, homeostasis model assessment; HR, heart rate; HT, hypertension; 
sICAM, soluble intercellular adhesion molecule; IGF-1, insulin-like growth factor-1; IR, insulin resistance; IL, interleukin; LDLc, low-density lipoprotein cholesterol; 
MDA, malonaldehyde; MPFF, micronized purified flavonoid fraction; MPI, milk protein isolate; NTG, nitro-glycerine-mediated dilation; PA, parallel design, PAI-1, 
plasminogen activator inhibitor-1; PCB, placebo, PBMCs, peripheral blood mononuclear cells; PS, plant sterols; PWV, pulse wave velocity; QUICKI, quantitative insulin 
sensitivity check index; SBP, systolic blood pressure; SOD, superoxide dismutase; TC, total cholesterol; TGF, transforming growth factor; T2D, type 2 diabetes; VCAM, 
soluble vascular cellular adhesion molecule; vWf, von Willebrand factor; X, crossover design. *Included after proofreading. 
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3.1. Simple Phenols 
3.1.1. Stilbenes 
Eight articles complied with requirements and their score varied from 3–5 and are included  
in Table 1. The age ranged from 20 until 83 years, with sample sizes of 19–166 participants.  
Two studies included an acute intervention design and were carried out in overweight/obese men and  
post-menopausal women with elevated BP [19,20]. Participants consumed three doses of resveratrol 
(RSV) (30 mg, 90 mg or 270 mg) or 75 mg of trans-resveratrol [20] and one hour after 
supplementation, they determined possible improvement of EF. Wong et al. [19] observed that EF 
increased more with the highest dose and later confirmed the increase of flow mediated dilation (FMD) 
with a 75 mg dose in an acute and a long term study [20]. One study was developed in healthy smoker 
subjects [21], testing the efficacy of RSV (500 mg/day) on anthropometric parameters and CHO 
metabolism, apart from lipid profile, markers of inflammation and oxidative stress during 60 days. 
Thus, after RSV supplementation, hsCRP and decreased, while antioxidant status (TAS) increased. 
Effects of short-term oral supplementation (60 days) of RSV alone (20 mg/day) or with calcium 
fructoborate (CF) (20 RSV + 112 CF mg/day) in subjects with stable angina pectoris were recently 
evaluated by Militaru et al. [22], measuring lipids profile, hsCRP, left ventricular function markers and 
observed a stronger decreased in N-terminal prohormone of brain natriuretic peptide (NT-proBNP) 
after RSV+CF administration. Moreover, RSV alone presented the most significant decreases for TC 
and TAG, although, reduction of high sensitivity C-reactive protein (hsCRP) was greater using CF 
treatment (112 mg/day). Tomé-Carneiro and colleagues [23–26] reported four studies with grape 
extract containing RSV combination (GE-RES), comparing with grape extract alone (GE). In 2012, 
they developed a clinical trial in primary prevention of CVD patients. After six months with  
350 mg/day GE or 350 mg/day GE-RES possible changes in lipid profile and oxidized LDL(oxLDL) 
were assessed [24] and then, doses were doubled for the next six months. LDLc, apolipoprotein B 
(ApoB), oxLDL, and oxLDL/ApoB ratio decreased in the GE-RES group, whereas non-HDLc (total 
atherogenic cholesterol load)/ApoB ratio increased. Moreover, they evaluated the effect in inflammatory 
and fibrinolytic biomarkers after one year [26]; many improvements were observed: hsCRP, tumour 
necrosis factor alpha (TNF-α), plasminogen activator inhibitor 1 (PAI-1), interleukin (IL) IL-6/IL-10 
ratio, and soluble intercellular adhesion molecule (sICAM) significantly decreased, and IL-10 and 
adiponectin increased. . In 2013, they evaluated the same doses (350 mg/day GE or 350 mg/day  
GE-RES), for the first six months and double for the following six months in patients with T2D, HT 
and stable coronary artery disease (CAD) [25], as well as in patients with stable CAD alone [23]. 
Peripheral blood mononuclear cells (PBMCs),inflammatory andfibrinolytic biomarkers were assessed 
in both studies; the pro-inflammatory cytokines CCL3, IL-1β and TNF-α expression levels, were 
significantly reduced and transcriptional repressor LRRFIP-1 expression increased in PBMCs from 
T2D, HT and stable CAD patients taking the GE-RES extract [25]. In the other trial, the GE-RES 
group showed an increase of the anti-inflammatory serum adiponectin and PAI-1 decreased. In addition, 
six key inflammation-related transcription factors were predicted to be significantly activated or 
inhibited, with 27 extracellular-space acting genes involved in inflammation, cell migration and T-cell 
interaction signals presenting down regulation in PBMCs from stable CAD patients [23]. 
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RSV has been shown to exert its protective effect against cardiovascular disease but it is necessary 
to reiterate that these data derive from cell culture or small animal model systems, with no reports on 
long-term health or survival in humans or alternate animal models [91]. It is well known that impaired 
FMD is recognized as an independent risk factor for the development of CVD [92,93]. Several authors 
investigated the acute resveratrol supplementation effect in overweight/obese individuals with mildly 
elevated BP, thus these subjects present cardiovascular risk [94,95]. Wong et al. [19] observed 
improvements in FMD were correlated with a dose-related increase in plasma RSV concentrations and 
following up their research, they confirmed the effect of RSV on FMD [20]. However, more long-term 
interventions are required. The other studies assessed long-term administration, until one year. 
Generally, trials obtained a decrease in total cholesterol (TC), triglycerides (TAG), C-reactive protein 
(CRP), CCL3, IL-1β, sICAM, NT-proBNP, TNF-α expression, LDLc, ApoB, LDLox and LDLox/ApoB 
ratio, as well as adiponectin, non-HDLc/ApoB ratio, IL-10 in different type of subjects [21–26]. 
Reports by Tomé-Carneiro et al. [23–26] focused on PBMCs, inflammatory andfibrinolytic 
biomarkers, lipid profile, and oxLDL concentration. Prior studies have shown increased mitochondrial 
production of ROS in PBMCs, endothelial cells, and other cell types in diabetes, suggesting systemic 
mitochondrial dysfunction [96,97]. Hartman et al. [98] observed higher basal, maximal, and uncoupled 
oxygen consumption in the diabetic patients, findings that are consistent with prior work showing 
increased mitochondrial ROS production in PBMCs. This suggests how serious complications may be 
in T2D subjects. Results by Tomé-Carneiro et al. [23,24] on transcriptional levels appear interesting; 
nevertheless, we have not found further similar interventions confirming these results. 
3.1.2. Catechols 
Two articles about catechols were selected (Table 1). According to the Jadad scale, such studies 
obtained values from 4–5. In 2008, Alwi et al. [27] assessed effects of curcumin on lipids profile in  
75 acute coronary syndrome (ACS) patients (45–73 years). The efficacy was measured using different 
doses (45 mg/day, 90 mg/day or 180 mg/day) during two months, reporting higher effects in TC, LDL 
reduction and an increase in HDL with the lower dose, but changes were not significant in respect to 
placebo. Recently, a study [28] also evaluated the efficacy and safety of curcumin extract  
(750 mg/day) as an intervention agent for reducing the risks for atherogenesis in 240 T2D patients with 
a mean age of 61 years, by means of parameters such as BP, anthropometry, lipids profile, adiponectin, 
leptin, CHO metabolism, uric acid, and pulse wave velocity (PWV). After six months, curcumin 
treatment significantly reduced PWV, homeostasis model assessment (HOMA), TAG, acid uric, leptin and 
abdominal obesity, as well as significantly elevated values of adiponectin. 
Alwi et al. [27] developed the first study to evaluate the effect of curcumin on the lipid profile of 
patients with ACS), thus the antecedents are described in in vitro and in vivo animal models. Results 
did not change significantly when comparing with placebo group. A meta-analysis based on five 
clinical trials in relation to curcumin on blood lipids concentration, indicated a non-significant effect  
of curcumin on the lipid profile when considering heterogeneous populations including healthy 
subjects, obese dyslipidemic patients, elderly subjects with established acute diagnosis of Alzheimer’s 
disease, ACS and patients with T2D [99]. Chuengsamarn et al. [28] also assessed lipid profiles and did 
not find significant statistic differences compared with placebo. Ramirez-Boscá et al. [100] observed 
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that a daily treatment with curcumin extract could decrease significantly the LDLc and ApoB 
concentrations and increase the HDL and ApoAI in healthy subjects. However, due to lack of 
sufficient data we cannot recommend curcuminoids for improvement lipids profile in healthy and 
unhealthy subjects until further solid evidence is obtained. 
On the other hand, after six months of curcumin intervention [28], PWV, HOMA, TAG, uric acid, 
abdominal obesity and leptin decreased, in addition to adiponectin increase. In addition, curcumin was 
well tolerated, with very few adverse effects. Agreeing with that, curcumin administration has been 
demonstrated, in in vitro and in vivo animal models, to elevate adiponectin and to decrease leptin 
levels [101,102], and oxidative stress in rabbits [14]. 
Due to its benefits and safety, Chuengsamarn et al. [28] proposed that curcumin extract might be 
used as anti-atherosclerotic in T2D populations. We propose however to replicate these results in other 
populations, since this study was performed  in a Thai population and high variabilities of physical 
activity and diet among populations may exist that affect study results. Moreover, there are not enough 
studies in humans for recommending curcumin against T2D. 
3.1.3. Beer or Wine Polyphenols 
Four of the studies were focused on the effects of polyphenols derived from beer or wine; all were 
in subjects with risk of CVD (55–75 years) (Table 1). They tested 280 mg of red wine polyphenols or 
30 g/day of beer or wine (normal and dealcoholized) for four weeks [29–32]. Botden et al. [29] 
analysed BP and found no significant effect. Chiva-Blanch et al. [30–32] reported that after the beer 
and non-alcoholic beer interventions the number of circulating endothelial progenitor cells  
(EPC)-mobilizing factors increased, consumption of dealcoholized red wine decreased BP and alcohol 
increased IL-10 and decreased macrophage-derived chemokine concentration and that the phenolic 
compounds of red wine decreased the serum concentrations of ICAM-1, E-selectin and IL-6. 
Botden et al. [29] studied the effects of polyphenols from wine on BP and found no effect except that, 
the use of dealcoholized red wine reduced BP. Moreover, phenolic compounds are related to decreases 
of inflammatory and vascular homeostasis biomarkers. Nevertheless, there is not strong evidence 
showing that consumption of beer or wine could help to improve risk of CVD; reports in the literature 
do not focus on a specific compound, regardless of alcohol content. A review by Rotondo et al. [103] states 
that wine in low quantities could be beneficial in regard to CVD, but notes possible bias in the 
publications reviewed. It is necessary to focus research on a specific compound in alcohol-containing 
products, when assessing for potential benefits in CVD. 
3.2. Polyphenols 
The different research equations resulted in 59 articles related to different flavonoids and 
subclasses, such as anthocyanins (ACN), flavonols, flavanols, isoflavones and procyanidins. Eight of 
the studies were discarded because of lack of information in the abstract or inability to obtain the  
full-text version. The results are presented in groups according to their class in Tables 2 and 3. 
  




Five publications were related to ACN (Table 2). Quality scores for these studies ranged from  
4 to 5 in the Jadad scale. Two of the studies were exclusively in women between 23 and 58 years [33,34] 
(sample sizes from 31 to 57) and one, in 31 hypertensive men aged between 35 and 51 years [35]. The 
study developed by Dohadwala and colleagues [36] was in patients with CAD using an acute and a 
chronic approach. 
The doses of ACN provided were from 500 to 640 mg/day [97,98] alone or as juice or blended 
drink including 94 mg/day [36], 983.7 mg/day and 840.9 mg/day [33], respectively, during periods from 
14 days to 4 weeks. 
The main outcomes in these studies were related to BP, lipid profile, CHO metabolism, 
inflammatory and oxidative stress biomarkers, platelet reactivity and vascular function. 
One of the studies reported an increase of HDLc and blood glucose after the ACN intake, but no 
effects on oxidative stress biomarkers [35]. On the other hand, Kuntz et al. [33] reported an increase 
on superoxide dismutase (SOD) and catalase (CAT) and a decrease of malonaldehyde (MDA) after the 
ACN ingestion. The other studies did not find any significant effect when analysing BP, CHO 
metabolism, lipid profile, inflammatory biomarkers, platelet reactivity [34] or vascular function [36]. 
A recent systematic review has shown the effectiveness of anthocyanins in decreasing CVD  
risk [104]. Nevertheless, in this review we found that improvement of risk factors related to CVD such 
as BP, lipids profile, CHO metabolism, inflammatory, oxidative stress biomarkers, and platelet 
reactivity were not consistent. Hassellund et al. [35] reported modifications in lipid and CHO 
metabolism, but this result was not supported in the other investigations, as was the case with oxidative 
stress as well. There is not strong evidence supporting that anthocyanins help to decrease risk of CVD 
and further studies are required, thus, the grade of recommendation according to the SIGN guidelines is B. 
3.2.2. Catechins 
Four of the studies were related to catechins (Table 2), and the quality score assigned according to 
the Jadad scale was around 3–5. Two of the studies were with healthy subjects between 32 and  
69 years old [37,38] (sample size 52 and 64 in each one). In regard to the other two studies, one 
included 52 subjects with early atherosclerosis (mean of 42 years of age) [39], and the other included 
240 subjects with visceral fat-type obesity aged around 25–55 years old [40]. 
In the studies with healthy subjects [37,38] and the one in visceral fat-type obesity [40],  
catechins were obtained from green and black tea, with doses between 583 mg and 3 g per day during 
periods between 4 and 14 weeks. The atherosclerotic subjects [39] were supplemented with 30 mL of 
epigallocatechin gallate (EGCG)-supplemented olive oil during 4 months. 
The main outcomes in the healthy subjects [37,38] were related to CVD risk, such as inflammatory 
and endothelial biomarkers. Subjects with early atherosclerosis [39] were investigated in regards to 
endothelial function and inflammatory and oxidative stress status. The aims in the subjects with 
visceral fat-type obesity [40] were anthropometric measurements, body fat composition and CVD  
risk factors. 
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There were no significant effects of the use of catechins in healthy subjects when compared with 
placebo/control; however, there was a negative correlation between beta-carotene and the inflammation 
biomarkers, IL-6 and fibrinogen [38]. On the other hand, the intervention in visceral fat-type obesity 
showed significant decreases in body weight, body mass index (BMI), body fat ratio, body fat mass, 
waist circumference (WC), hip circumference, visceral fat area and subcutaneous fat area, systolic 
blood pressure (SBP) and LDL cholesterol [40]. Nevertheless, in patients with early atherosclerosis, 
there was no significant effect, but merging both, the control (olive oil) and the experimental group 
(olive oil and EGCG)) the endothelial function was improved [39]. 
Catechins were shown to be effective in reducing LDLc and TC, but there is no robust evidence in 
reducing CAD risk [105]; a dose of 583 mg of catechins in middle-aged subjects showed a significant 
effect reducing obesity related makers, such as body weight, BMI, body fat ratio, body fat mass, WC, 
hip circumference, visceral fat area, and subcutaneous fat area, SBP, LDLc. However, doses of 630 mg 
or 3 g did not benefit middle and older aged subjects. Furthermore, Widmer et al. [39] investigated the 
effects of olive oil with EGCG in endothelial function without significant effect; however, they found 
a significant improvement when they merged both study groups. Nevertheless, this result is attributable 
to olive oil compounds, independently of the EGCG content. Taking into account the different studies 
included in this review, we can conclude that there is no robust evidence to suggest a beneficial effect 
of tea catechins on prevention of CVD; consequently, the grade of recommendation according to the 
SIGN guidelines is B. 
3.2.3. Flavanols 
Fourteen investigations studied the effects of flavanols (Table 2); the Jadad quality scores were between 
3 and 5. Only one study was in healthy males (mean 68 years, and with a sample size of 40) [41], while 
four papers were related to overweight adults (with one of them including two designs and thus treated 
as separated studies [45]), involving subjects from 40 to 64 years (n = 21–98) [42,43]. Furthermore, 
there were two studies in hypertensive subjects [46,47] with 52 and 19 patients respectively. The study 
developed by Flammer et al. [48] included 20 chronic heart failure (CHF) patients (58 years mean) 
with an acute and a long-term intervention. Heiss et al. [49] and Horn et al. [50] studied the effect of 
flavanol in 16 CAD patients (60 years mean) while Balzer et al. [51] designed a study in diabetic 
patients with an acute and long-term intervention (10–41 subjects between 50 and 80 years). 
Four of the studies [42,45,48,51] used a short-term approach looking for the acute response of 
flavanols; they tested cocoa or chocolate in amounts from 624 mg to 963 mg/day. Further, the other 
studies tested the flavanols contained in chocolate in longer interventions, from 4 to 6 weeks in doses 
from 33 to 1052 mg/day [43,44,46]. 
The aim of the study in healthy males [41] was to determine the effect on the endothelial function 
and in the soluble cellular adhesion molecules, without significant effects. In regards the studies with 
overweight [42,43,45], hypertensive [46,47], CHF [48], CAD [49,50] and diabetic patients [51], the 
main outcomes were related to EF and BP. Furthermore, Grassi et al. [47] studied the effects on lipids 
profile and IR. 
The results in overweight, HT, CHF, CAD and diabetic patients showed a consistent improvement 
in EF when comparing different doses of flavanols vs. placebo/control [42–45,47–51]. 
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When testing flavanols in BP, Faridi et al. [29] found a significant decrease in BP in overweight 
adults in an acute intervention with two different products using >800 mg/day of flavanols. 
Additionally, BP decreased significantly in hypertensive subjects using flavanol-rich chocolate during 
15 days [47] and in CAD patients [49] with 375 mg twice daily during 30 days. However, this result 
was not consistent when using doses between 33 and 1052 mg/day of flavanones during six weeks [46] 
or 814 mg/day during four weeks [44]. Besides, Berry et al. [42] found out that cocoa flavanols could 
attenuate the increase of BP after exercise. The effects on IR were investigated in two studies, finding 
a significant improvement [43,47].  
Flavanol-rich chocolate and cocoa products have shown a small but statistically significant effect  
in lowering blood pressure by 2–3 mm Hg in the short term [101], in addition Khawaja et al. [106] 
suggest that there is ample evidence in support of the beneficial effects of cocoa/dark chocolate on 
CHD risk. Summary of the evidence showed benefits of cocoa flavanols in BP and EF, in overweight  
adults [42–46], hypertensive subjects [47], in CHF [48], in CAD [49,50] and in T2D patients [51] 
utilizing different doses (149–963 mg/day). Additionally, Balzer et al. [51] reported a dose-response in 
an acute intervention. While the use of cocoa flavanols in BP and EF improvement have shown 
efficacy, further studies using flavanol-free controls could help to strength the evidence and long-term 
interventions may clarify the effect on CVD, thus the grade of recommendation according to the SIGN 
guidelines is B. 
3.2.4. Flavonols 
Five studies were focused on the effects of flavonols on CVD (Table 2); all of them obtained more 
than 3 points in the Jadad scale. Three of the publications were focused on healthy males [52–54] aged 
between 24 and 53 years (sample size between 12–27). The other two studies studied the effect on 
hypertensive subjects [52,55] (24–49 years; including 12 and 41 subjects, each one). Quercetin was the 
flavonol tested in two of the healthy subject studies at a dose of 1 g/day; Larson et al. [52] used it in an 
acute study and Conquer et al. [53] used it for 28 days; both of the authors looked for effects in BP and 
vascular markers without effect. Moreover, Suomela et al. [54] utilized oatmeal with 78 mg of 
flavonol aglycones from sea buckthorn for four weeks, and likewise did not find any significant effect. 
The studies focused on hypertensive subjects looked for effects in BP, oxidative stress,  
angiotensin-converting enzyme and endothelin. Both, Edwards and Larson [52,55] found a significant 
reduction in BP in hypertension. Evidence around flavonol has been controversial; previous  
meta-analyses has associated its consumption with lower rates of CHD [8] or a reduction in risk of 
stroke [107,108], but reports from other authors do not support the protective role against CHD [10]. In 
the present review, we have found that doses of 1 g/day of quercetin or an oatmeal with 78 mg of 
aglycones of quercetin did not shown effects on diverse CVD risk markers, such as endothelin, BP or 
oxidative stress. Nevertheless, an acute intervention with 1095 mg/of quercetin and a long-term 
intervention (28 days) with 730 mg/day seems to be effective at reducing BP in hypertensive  
men [52,55], but not on other oxidative stress or endothelial function markers. We can conclude that 
there is no effect of flavonols in CHD, thus the grade of recommendation according to the SIGN 
guidelines is B, but since it seems that flavonols are effective at reducing BP in hypertensive men, 
further analysis in greater cohorts are needed. 




Thirty papers were related to the consumption of isoflavones (Table 3), the Jadad scores were above 
three points. Five of the studies were in healthy subjects between 20 and 53 years  
(sample size 22–205) [56,57,59,60,68]. Most of the studies were developed in postmenopausal  
women (45–92 years) with normal weight [61–67], overweight and obese [69–71], with BP  
alterations [78,109], dyslipidaemias [76,77,79] or T2D [80], including from 40 to 350 participants. 
Other authors also took men in account [58,72–75]. One study investigated in 102 subjects prior to 
ischemic stroke [81] (mean 66 years), another in 71 subjects with CAD (mean 58) [82] and Fanti and 
colleagues studied the effect on patients with systemic inflammation [83]. 
The doses of isoflavones employed in healthy subjects and postmenopausal women were between 
40 and 118 mg/day, with lengths between 17 days to two years. The intervention in postmenopausal 
women with T2D used 100 mg/day of isoflavones for a one-year period. The subjects with ischemic 
stroke consumed 80 mg/day of isoflavones for 12 weeks. Patients with CAD included 75 mg/day 
during five days. Subjects with systemic inflammation included doses between 26–54 mg/day of 
isoflavones aglycones [56–80,109]. 
The main outcomes established in the articles of healthy, overweight and obese subjects were 
related to anthropometry [66], body composition [63,70,71,109], lipid profile [56–60,62,63,65–70], 
BP, CHO metabolism [60,62,63,66,70], and inflammatory [57,59,63,64,67], oxidative stress [62] and 
vascular homeostasis biomarkers [59,62,64] and only one in atherosclerosis progression [61]. Besides, 
the studies in hypertensive and dyslipidemic patients aimed on lipids profile [73,74,76,79],  
BP [73,75,76,78,79], oxidative stress [72,74,76], endothelial function [75,78] and just one in vascular 
inflammation biomarkers [77]. Two articles from Curtis et al. [80,110] in postmenopausal women with 
T2D looked for effects in HOMA, QUICKI, lipids profile, intima-media thickness of the common 
carotid artery, pulse wave velocity, augmentation index, BP, and vascular biomarkers. 
The results reported in healthy, overweight and obese patients related to anthropometry and body 
composition were without significant effects of isoflavones. Moreover, in relation with lipids profile, a 
study reported lower ratios of TC/HDLc, LDLc/HDLc, and ApoB/Apo A-I [56] and another a decrease 
in TC and LDLc [71]. Besides, Sanders et al. [57] found significant improvements in HDLc and Apo-A; 
however, seven studies did not find any significant effect in plasma/serum lipids [58–60,63,65–67,69]. 
Fasting glucose, insulin, and HOMA were reduced in three studies [59,60,66] but results from other 
authors were not consistent [63,69,70]. The only author that studied BP [63] did not find any 
significant change. Atteritano et al. [62] reported significant improvements in isoprostanes  
(8-iso-PGF2α), sICAM-1 and soluble vascular cell adhesion molecule-1, while Atkinson et al. [59] and 
Sanders [57] investigated PAI-1 and other authors [72,74] 8-iso-PGF2α without significant results. 
One study showed a decrease in thromboxane A2 [63] and another in CRP [64]. The study of Liu et al. [67] 
aimed in inflammatory markers showed no effect. Hodis et al. [61] analysed atherosclerosis 
progression finding no positive effects. Furthermore, in subjects with BP alterations and 
dyslipidaemias, there were no significant changes in CHO metabolism [79,80], oxidative stress or 
inflammatory biomarkers [72,74,76,77]. In relation to BP, Sagara et al. [73] and Teede et al. [78] 
reported improvements; nevertheless, these results were not consistent with the results obtained by 
other authors [75,76,79,80]. Moreover, when lipid profile were analysed, a decrease in total cholesterol, 
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LDLc and a decrease was observed [73,76,79] but Meyer et al. [75] and Thorp et al. [58] reported no 
significant change. Many authors [52,56,57,108] described no significant effects on endothelial 
function; nonetheless, Jenkins et al. [76] reported a lower calculated risk of CAD. The intervention in 
subjects’ prior ischemic stroke [81] found a reduction in hsCRP and improved the EF, beside CAD  
patients [82] showed no effect on EF. Fanti et al. [83] found a significant inverse correlation between 
isoflavones and CRP. 
The use of isoflavones on the prevention of CVD has been associated with the capacity of these 
compounds to attenuate alterations in lipid profile and inflammatory markers [111,112]. Furthermore, the 
American Diet Association recommended consumption of soy protein containing isoflavones in high-risk 
populations with increased total cholesterol and LDLc. Additionally, data from two cohorts [113,114] 
showed that isoflavones consumption is associated with a lower risk of cardiovascular disease in 
women. Interestingly, we found that doses above 50 mg/day in healthy subjects improved lipids 
profiles [56,57,68], but a lower dose for 12 months did not show effect on CVD risk factors [45]. 
Additionally, normal weight postmenopausal women did not improve the lipid profile in many of the 
studies in which they included as outcome [60,63,65–67,69]. Nevertheless, the response of 
dyslipidemic postmenopausal women was positive when treated with doses between 60 and 80 mg/day 
of isoflavones, decreasing TC, HDLc and ratios TC/HDLc, LDLc/HDLc and ApoB/A-I [76,79]. 
Glucose, insulin and HOMA measurement are important due to its relationship in development of 
CVD. Although, these indicators were reduced in normal weight subjects [41,43,49], isoflavones in high 
doses (60–100 mg/day) showed no benefit on overweight/obese postmenopausal women [63,69,70,79]. 
BP was only measured by Garrido et al. [63] in healthy subjects without significant changes.  
A different panorama was shown in subjects with BP and dyslipidaemias, while doses above 80 mg 
improved BP [73,78], doses below did not have any effect [75,76,79,80]. 
The research focused on inflammatory and oxidative stress biomarkers in healthy subjects  
gave inconclusive results, markers such as fibrinogen and PAI-1 were not reduced, but only two 
authors measured them [57,59]. Thromboxane A2, CRP, and 8-iso-PGF2α were markers that also 
responded effectively to isoflavones intervention, but were not taken in account in all the 
investigations [57,59,60,62–64,67,71]. Moreover, Liu et al. [109] focused his research in measuring 
inflammatory markers after an intervention with soy or milk protein plus 100 mg of isoflavones 
without significant effects. This lack of consistent results was already showed by Dong and  
colleagues [114] in a meta-analysis including 14 trials that analysed soy foods with isoflavones 
concluded that there is insufficient evidence that soy isoflavones significantly reduce CRP 
concentrations in postmenopausal women. 
Dysfunction of the vascular endothelium has shown to be an early step prior to development of 
atherosclerosis [115], its prevention is vital for the maintenance of vascular health. Some authors 
reported no EF improvement [65,74,75,80], indeed, Webb et al. [82] conclude a lack of effect on EF in 
their intervention; however, the inclusion of more women to perform a specific gender analysis could 
give different results. Nevertheless, Chang et al. demonstrated that 12-week isoflavone treatment 
improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their 
endothelial dysfunction status. In this regard, Li et al. [9] developed a meta-analysis measuring 
isoflavones on vascular endothelial function in postmenopausal women and conclude that oral 
isoflavone supplementation does not improve endothelial function in postmenopausal women with 
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high baseline FMD levels but leads to significant improvement in women with low baseline FMD 
levels. Furthermore, Pase et al. [116] determined that soy isoflavone supplementation provides an 
effective means of reducing arterial stiffness, but this review showed to be biased. 
Lastly, the use of isoflavones in body composition and anthropometric measurements showed no 
effect in most of the interventions that included study of outcomes [63,66,67,69,70]. In summary, the 
need of further studies with greater population sizes are necessary; the effect of the inflammatory 
process and endothelial function in postmenopausal women on are possibly the most interesting areas 
of study. The grade of recommendation according to the SIGN guidelines is B. 
3.2.6. Procyanidins 
Eight studies from the search were related to procyanidins (Table 3), with a Jadad score above  
three points. Two interventions were in healthy subjects between 34 and 75 years [84,85], sample size 60 
and 70, in each one. Asher et al. [86] and Liu [87] studied the effects of procyanidins in HT and the 
three other studies were in CAD (18–73 years, sample size of 23 and 50) and the last study included 
209 chronic stable New York Heart Association class-III heart failure subjects [90]. 
The interventions in healthy subjects used 300–700 mg/day of grape extracts with a length of eight 
weeks in both [84,85]. In HT subjects, the hawthorn extract was investigated in a short tem study of 
three and a half days in doses of 1 g, 1.5 and 2.5 g [86]. In the other study they used  
100 mg/day of Pycnogenol® during 12 weeks [87]; this product was also utilized at a dose of  
200 mg/day in stable CAD patients for eight weeks [88]. Besides, muscadine grape seed was used for 
four weeks in doses of 1300 mg/day [89]. The subjects with stable CHF were treated with  
1800 mg of crataegus extract WS 1442 or 900 mg of crataegus extract WS 1442 or with placebo for 16 
weeks [90]. 
In healthy subjects, the outcomes were related to BP, CVD and oxidative stress biomarkers, in 
hypertensive subjects to endothelial function, in CAD to endothelial function, inflammatory and 
oxidative stress biomarkers. In patients with stable CHF, the aim was related to typical heart failure 
symptoms [84–88,90]. 
There were no significant effects in BP in healthy subjects [84]. However, Yubero et al. [85] reported a 
significant decrease in TC, LDL and an increase in TAC and vitamin E. Furthermore, in hypertensive 
subjects, Asher et al. [86] did not find significant effects, while on the contrary Liu et al [87] found a 
reduction of endothelin-1 concentration and an increase in 6-keto prostaglandin F1a. Moreover, the use 
of Pycnogenol in CAD also showed an improvement of endothelial function and a reduction of  
8-iso-PGF2α [88]. The muscadine grape seed did not show any significant effect [89] and the 
crataegus extract seemed to reduce the typical heart failure symptoms [90]. 
Procyanidins are compounds that can stabilize membranes, preventing their disruption by chemical 
and biological agents, thus mitigating oxidative stress and the activation of proinflammatory signals, 
factors related to development of CVD. Evidence found in the literature reviewed is not consistent.  
In healthy subjects, there was no effect on BP [84] using 300 mg/day of grape seed extract. However, 
Yubero et al. [85] reported improvement on CVD risk and oxidative stress markers with 700 mg/day. 
Besides, in hypertensive subjects, one study including different doses showed no improvements in EF 
or NO release, while another with 100 mg of Pycnogenol® reduced the concentration of endothelin and  
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6-keto prostaglandin F1a. The same compound was utilized in a dose of 200 mg/day in patients with 
stable CAD with improvements in EF and a decrease in isoprostanes. However, Mellen et al. [89] studied 
the effect of muscadine grape seed (1300 mg) without further effects. Finally, Tauchert et al. [90] included 
two different extracts from crataegus in typical heart failure symptoms with a positive decrease as 
rated by patients. In this regard, there is insufficient evidence to determine if extracts containing 
procyanidins could improve CVD risk; further investigations are necessary for more homogenous 
outcomes and greater populations; therefore, the grade of recommendation is C. 
4. Limitations and Future Perspectives 
Certain limitations need to be considered. Firstly, MeSH terms are not often used by researchers. 
Such specific terms must be taken into account when articles are drafted and assuring a good 
indexation and more visibility, facilitating the evidence valuation. Secondly, the application of 
resources such as CONSORT (Consolidated Standards of Reporting Trials) statement or Jadad scale is 
highly scarce. Moreover, the existence of checklists helps authors and editors to improve the reporting 
of RCTs and consequently provides scientific quality in data reports. We consider that a clinical trial is 
reliable when it is at least randomized and blinded. In addition, the trials included in this review have 
high levels of heterogeneity, making it more difficult to draw concrete conclusions in relation to types 
of subjects, form of analysed product or its combination with other compounds. 
Future studies must show better designs to avoid the risk of bias usually associated with potential 
confounding variables such as other dietary or lifestyle factors. In addition, the dosages, polyphenol 
type, duration and frequency of consumption must be clear, giving the opportunity to assess the 
possible benefits to a specific compound. Long-term, double-blind, crossover, randomized clinical 
trials with specific clinical endpoints should be developed to guarantee the possible benefits of 
phenolic BAC. 
In addition, the use of potent new technologies such as omics sciences i.e. transcriptomics, 
metabolomics, could help to elucidate the different mechanisms in which BAC are involved in CVD 
and its specific role. 
5. Conclusions 
The role of BAC as adjuvants in CVD is increasing and validation of its effects is essential. 
Evidence shows that some polyphenols used as BAC such as flavonols are helpful in decreasing  
risk factors of CVD. However, it is necessary to develop better quality RCTs (crossover design, 
double-blinded, long term, placebo/controlled) as well as elaborate rigorous meta-analysis of existing 
evidence to support the effect of BAC on the prevention and treatment of CVD. 
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